In the Lead-Up to Rare Disease Day, CENTOGENE Expands Observational Study to Advance…
<!-- Name:DistributionId Value:8753420 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->…
Browsing Tag
FTD
Amydis Receives NIH Grant Award to Develop a Novel TDP-43 Retinal Tracer in Patients…
SAN DIEGO, Aug. 18, 2022 (GLOBE NEWSWIRE) -- Amydis Inc., a leading ocular tracer pharmaceutical company with a broad portfolio of diagnostic drug candidates targeting CNS biomarkers in…
Wave Life Sciences Announces Publication of Foundational Preclinical Data Supporting…
Preclinical data published in Molecular Therapy Nucleic Acids demonstrate that WVE-004 potently reduces C9orf72 transcriptional variants and poly(GP) dipeptide repeat proteins in mice for…
Valentine’s Day Flower Prices Climb as Inflation Hits Wholesalers, Retailers
Flower sellers say they are asking price-conscious shoppers to consider less-traditional Valentine’s Day bouquets, including shorter-stemmed roses, not-red roses or different flowers.…
CENTOGENE Enrolls First Patient in Frontotemporal Dementia (FTD) Clinical Study
FTD is a rapidly progressing neurodegenerative disease; up to 30% of all cases worldwide caused by genetic mutations, including the progranulin gene mutation (FTD-GRN)Study will enroll and…
Amydis Receives NIH Grant Award to Develop a Novel Tau Retinal Tracer for…
SAN DIEGO, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Amydis Inc., a leading ocular tracer pharmaceutical company with a broad portfolio of diagnostic drug candidates targeting CNS biomarkers in…